Division of Royal Philips NV
Latest From AngioScore Inc.
Healthy market growth, the biggest ever M&A deal, a record number of billion-dollar takeovers, and the IPO market in impressive bounce-back…2014 was a year of superlatives for the global medtech industry. But with more expected of manufacturers while health care spending remains in the doldrums and demand for care rises, the long-term medtech winners will be those who can forecast how and where to make an impact on both costs and patient outcomes.
Medtech manufacturers saw 2014 as the year of the medtech mega-merger and a rebound in IPOs. But the market is changing, and companies are increasingly cast as service providers who must deliver value.
Device funding increased 123% to $1.6 billion in Q2, and M&A activity was overshadowed by Medtronic’s massive $47 billion acquisition of Covidien. Diagnostics fundraising dropped slightly to $522 million, and there were multiple takeovers of life sciences companies.
As Valeant continues its pursuit of Allergan, the spec pharma divested its aesthetics products to Galderma for $1.4 billion; Merck and Boston Scientific also sold off major OTC and interventional businesses, respectively. Biopharma funding was down from the previous month to just over $1 billion, while device financing was slightly up to $390 million.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Royal Philips NV
- Senior Management
Thomas R Trotter, Pres. & CEO
James B Andrews, SVP, CFO
Gary Gershony, MD, CMO
Richard P Cassidy, SVP, Global Sales & Marketing
Kent W Jones, SVP, Regulatory & Quality
Samuel L Omaleki, SVP, Operations
Jeff Bleam, VP, R&D
- Contact Info
Phone: (510) 933-7900
5055 Brandin Ct.
Fremont, CA 94538
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.